Using a large sample from the European Society for Blood and Marrow Transplantation (EBMT) registry, we investigated the predictive factors of posttransplant outcomes in patients with normal karyotype NPM1‐mutated AML with specific emphasis on the individual and aggregate roles of MRD status before transplant, FLT3‐ITD mutation status, and disease status at transplant. This evidence concerns the gene NPM1 and acute myeloid leukemia.